Ironwood Pharmaceuticals

Ironwood Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing therapies for gastrointestinal (GI) diseases. The company discovered and developed linaclotide (LINZESS), an approved treatment for irritable bowel syndrome with constipation (IBS‑C) and chronic idiopathic constipation, and advances additional programs targeting digestion, motility and visceral pain. Ironwood combines in‑house research and clinical development with commercial partnerships to bring treatments to patients and is headquartered in the Boston, Massachusetts area. The company emphasizes patient‑focused research, scientific innovation, and long‑term commitment to improving digestive health.